Safety Board Recommends Trial of Anavex 2-73 Continues as Planned

Safety Board Recommends Trial of Anavex 2-73 Continues as Planned

309123

Safety Board Recommends Trial of Anavex 2-73 Continues as Planned

After reviewing interim trial data, an independent safety board has recommended that Anavex Life Sciences continues a trial, without modification, of its oral therapy Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease. The board made a similar recommendation after an interim analysis earlier this year. Such a committee comprises a group of external experts tasked with monitoring clinical trials to ensure the safety of participants and the integrity of the data. Anavex is expecting that top-line…

You must be logged in to read/download the full post.